China-based Shenzhen YHLO Biotech Co., Ltd has announced a strategic partnership with the National Clinical Research Center for Infectious Diseases (NCRCID) to develop advanced tuberculosis diagnosis products. The collaboration aims to leverage both entities’ expertise to enhance diagnostics in the field of infectious diseases, with a focus on tuberculosis. Financial details of the agreement have not been disclosed.
NCRCID: A Leader in Infectious Diseases Research
NCRCID, the sole national clinical research center in Shenzhen, is dedicated to the prevention and treatment of infectious diseases, with a particular emphasis on tuberculosis. Its focus on clinical research and treatment makes it a key player in advancing healthcare solutions for infectious diseases in the region.
YHLO Bio’s Comprehensive IVD Product Portfolio
Founded in 2008, YHLO Bio is a leading company in the research and development, manufacturing, marketing, and sales of in vitro diagnosis (IVD) products. The company has established itself with a range of IVD technology platforms, including chemiluminescence, fluorescence immunochromatography, enzyme-linked immunosorbent assay, immunoblotting, indirect immunofluorescence, and colloidal gold immunochromatography. YHLO Bio’s product portfolio comprises over 300 products, covering a broad spectrum of areas such as autoimmune diseases, infection immunity, and liver disease detection.-Fineline Info & Tech
